261 related articles for article (PubMed ID: 38398101)
1. Role of Epiregulin in Lung Tumorigenesis and Therapeutic Resistance.
Sunaga N; Miura Y; Masuda T; Sakurai R
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398101
[TBL] [Abstract][Full Text] [Related]
2. Epiregulin as a therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K
Lung Cancer (Auckl); 2015; 6():91-98. PubMed ID: 28210154
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
4. The Role of EREG/EGFR Pathway in Tumor Progression.
Cheng WL; Feng PH; Lee KY; Chen KY; Sun WL; Van Hiep N; Luo CS; Wu SM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884633
[TBL] [Abstract][Full Text] [Related]
5. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling.
Iijima M; Anai M; Kodama T; Shibasaki Y
Biochem Biophys Res Commun; 2017 Jul; 489(1):83-88. PubMed ID: 28274874
[TBL] [Abstract][Full Text] [Related]
6. Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer.
Ma S; Zhang L; Ren Y; Dai W; Chen T; Luo L; Zeng J; Mi K; Lang J; Cao B
Oncogene; 2021 Apr; 40(14):2596-2609. PubMed ID: 33750895
[TBL] [Abstract][Full Text] [Related]
7. Epiregulin promotes hair growth via EGFR-medicated epidermal and ErbB4-mediated dermal stimulation.
Choi N; Kim WS; Oh SH; Sung JH
Cell Prolif; 2020 Sep; 53(9):e12881. PubMed ID: 32700456
[TBL] [Abstract][Full Text] [Related]
8. Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
Bade LK; Goldberg JE; Dehut HA; Hall MK; Schwertfeger KL
J Cell Sci; 2011 Sep; 124(Pt 18):3106-17. PubMed ID: 21868365
[TBL] [Abstract][Full Text] [Related]
9. Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.
Farooqui M; Bohrer LR; Brady NJ; Chuntova P; Kemp SE; Wardwell CT; Nelson AC; Schwertfeger KL
Mol Cancer; 2015 Jul; 14():138. PubMed ID: 26215578
[TBL] [Abstract][Full Text] [Related]
10. Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.
Xu X; Chen W; Leng S; Padilla MT; Saxton B; Hutt J; Tessema M; Kato K; Kim KC; Belinsky SA; Lin Y
Carcinogenesis; 2017 Jun; 38(6):604-614. PubMed ID: 28472347
[TBL] [Abstract][Full Text] [Related]
11. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
12. 3-Nitrobenzanthrone promotes malignant transformation in human lung epithelial cells through the epiregulin-signaling pathway.
Chen KY; Tseng CH; Feng PH; Sun WL; Ho SC; Lin CW; Van Hiep N; Luo CS; Tseng YH; Chen TT; Liu WT; Lee KY; Wu SM
Cell Biol Toxicol; 2022 Oct; 38(5):865-887. PubMed ID: 34036453
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
15. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
16. Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma.
Liu S; Ye D; Xu D; Liao Y; Zhang L; Liu L; Yu W; Wang Y; He Y; Hu J; Guo W; Wang T; Sun B; Song H; Yin H; Liu J; Wu Y; Zhu H; Zhou BP; Deng J; Zhang Z
Oncotarget; 2016 May; 7(18):25251-63. PubMed ID: 26958807
[TBL] [Abstract][Full Text] [Related]
17. Epiregulin (EREG) is upregulated through an IL-1β autocrine loop in Caco-2 epithelial cells with reduced CFTR function.
Massip-Copiz M; Clauzure M; Valdivieso ÁG; Santa-Coloma TA
J Cell Biochem; 2018 Mar; 119(3):2911-2922. PubMed ID: 29091309
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.
Zhang J; Iwanaga K; Choi KC; Wislez M; Raso MG; Wei W; Wistuba II; Kurie JM
Cancer Prev Res (Phila); 2008 Aug; 1(3):201-7. PubMed ID: 19138957
[TBL] [Abstract][Full Text] [Related]
19. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Qu X; Sandmann T; Frierson H; Fu L; Fuentes E; Walter K; Okrah K; Rumpel C; Moskaluk C; Lu S; Wang Y; Bourgon R; Penuel E; Pirzkall A; Amler L; Lackner MR; Tabernero J; Hampton GM; Kabbarah O
Oncogene; 2016 Dec; 35(50):6403-6415. PubMed ID: 27270421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
